Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2018

View Archived Issues

Chugai reflects on accomplishments of fourth quarter 2017

Astellas updates regulatory and clinical developments of third quarter of fiscal 2017

IRLAB provides update on its lead development programs, IRL-752 and IRL-790

Ozempic and Fiasp launched in the U.S.

Topline results from phase IIb study of EGP-437

Phase III ADVANCE study of Rolontis meets primary endpoint

SapVax announces its most recent achievements

Acticor Biotech's phase I study of ACT-017 meets endpoints

FDA expands indication for AMAG's Feraheme

TBX15 identified as predictor of poor survival in HCC patients

Oricula Therapeutics cleared to begin clinical testing of ORC-13661 in U.S.

Paratek Pharmaceuticals submits omadacycline NDAs in U.S.

Survival endpoint met with nab-paclitaxel regimen in biliary tract cancer trial

Jupiter Orphan Therapeutics preparing INDs for Jotrol

FDA clears Trethera's TRE-515 IND

Fibrocell Science submits IND for gene therapy candidate for scleroderma

EMA accepts Epidiolex MAA for review

V1B receptor antagonism may enhance alcohol dependency treatment

First patient dosed in phase Ib/II aldoxorubicin combination study

Redx Pharma initiates phase I/IIa trial of RXC-004 in hard to treat cancers

Lilly identifies new JAK1 inhibitors

Medshine Discovery patents nitroimidazole derivatives

New isocitrate dehydrogenase inhibitors described by Nanjing Sanhome Pharmaceutical

Italfarmaco divulges novel benzo-N-hydroxy amide compounds

Incyte discovers new PD-1/PD-L1 interaction inhibitors

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...